199 related articles for article (PubMed ID: 29135656)
1. Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis.
Mugwanya KK; Baeten JM; Wyatt C; Mugo NR; Celum CL; Ronald A; Kiarie J; Katabira E; Heffron R;
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):206-211. PubMed ID: 29135656
[TBL] [Abstract][Full Text] [Related]
2. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
[TBL] [Abstract][Full Text] [Related]
3. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.
Schaefer R; Amparo da Costa Leite PH; Silva R; Abdool Karim Q; Akolo C; Cáceres CF; Dourado I; Green K; Hettema A; Hoornenborg E; Jana S; Kerschberger B; Mahler H; Matse S; McManus H; Molina JM; Reza-Paul S; Azwa I; Shahmanesh M; Taylor D; Vega-Ramirez H; Veloso VG; Baggaley R; Dalal S
Lancet HIV; 2022 Apr; 9(4):e242-e253. PubMed ID: 35271825
[TBL] [Abstract][Full Text] [Related]
4. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
5. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
6. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
[TBL] [Abstract][Full Text] [Related]
8. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
9. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
10. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
11. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
Jotwani V; Scherzer R; Glidden DV; Mehrotra M; Defechereux P; Liu A; Gandhi M; Bennett M; Coca SG; Parikh CR; Grant RM; Shlipak MG
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):169-174. PubMed ID: 29767638
[TBL] [Abstract][Full Text] [Related]
12. Development of normal reference intervals for renal function in pregnancy: a secondary analysis of clinical trial data.
Legoabe Z; Sebitloane M; Lombard C; Naidoo M; Gray G; Moodley D
J Obstet Gynaecol; 2024 Dec; 44(1):2361445. PubMed ID: 38832538
[TBL] [Abstract][Full Text] [Related]
13. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Kiarie J; Ronald A; Baeten JM;
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):374-80. PubMed ID: 26914909
[TBL] [Abstract][Full Text] [Related]
14. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
Mugwanya KK; John-Stewart G; Baeten J
Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500
[TBL] [Abstract][Full Text] [Related]
15. HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.
Ascher SB; Scherzer R; Estrella MM; Shigenaga J; Spaulding KA; Glidden DV; Mehrotra ML; Defechereux P; Gandhi M; Grant RM; Shlipak MG; Jotwani V
AIDS; 2020 Apr; 34(5):699-706. PubMed ID: 31794523
[TBL] [Abstract][Full Text] [Related]
16. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
Solomon MM; Lama JR; Glidden DV; Mulligan K; McMahan V; Liu AY; Guanira JV; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Burns DN; Grant RM;
AIDS; 2014 Mar; 28(6):851-9. PubMed ID: 24499951
[TBL] [Abstract][Full Text] [Related]
17. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG
AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929
[TBL] [Abstract][Full Text] [Related]
18. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.
Heffron R; McClelland RS; Balkus JE; Celum C; Cohen CR; Mugo N; Bukusi E; Donnell D; Lingappa J; Kiarie J; Fiedler T; Munch M; Fredricks DN; Baeten JM;
Lancet HIV; 2017 Oct; 4(10):e449-e456. PubMed ID: 28732773
[TBL] [Abstract][Full Text] [Related]
20. Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.
Drak D; Barratt H; Templeton DJ; O'Connor CC; Gracey DM
PLoS One; 2019; 14(1):e0210106. PubMed ID: 30653509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
